Acute myocardial infarction: The case for pre-hospital thrombolysis with or without percutaneous coronary intervention

Heart

Volumn 91, Issue SUPPL. 3, 2005, Pages

  Schofield, Peter M ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ANGIOPLASTY; CLINICAL TRIAL; CORONARY STENT; DRUG EFFICACY; EVALUATION; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SAFETY; STENOSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; EMERGENCY MEDICAL SERVICES; EMERGENCY TREATMENT; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 20044364051     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.058529     Document Type: Review

References (24)

1. Department of Health. National service framework for coronary heart disease. London: Department of Health, 2000.
2. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
3. Gulba DC, Tanswell P, Dechend R, et al. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997;30:1611-7.
4. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
6. Fath-Ordoubadi F, Huehns T, Al-Mohammad A, et al. Significance of the thrombolysis in myocardial infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J 1997;134:62-8.
7. Stringer KA. TIMI grade flow, mortality, and the GUSTO-III trial. Pharmacotherapy 1998;18:699-705.
8. Meijer A, Verheugt FW, Werter G, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993;87:1524-30.
9. Anon. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
10. Leslie WS, Urie A, Hooper J, et al. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care. Heart 2000;84:137-41.
11. Brouwer MA, Martin JS, Maynard C, et al. Influence of early prehospital thrombolysis on mortality and event-free survival (the myocardial infarction triage and intervention [MITI] randomized trial). MITI project investigators. Am J Cardiol 1996;78:497-502.
12. The European Myocardial Infarction Project Group. Pre hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329:383-9.
13. Weaver WD, Simes RJ, Bertriu A. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-8.
14. Stone GW, Grines CL, Browne KF. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the primary angioplasty in myocardial infarction (PAMI) trial. J Am Coll Cardiol 1995;25:370-7.
15. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
16. Maillard L, Hamon M, Khalife K, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol 2000;35:1729-36.
17. Stone GW, Grines CL, Rothbaume D, et al. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the primary angioplasty in myocardial infarction (PAMI) trial. The PAMI trial investigators. J Am Coll Cardiol 1997;29:901-7.
18. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-actingthrombolysis and immediate planned rescue angioplasty in acute myocardialinfarction: the PACT trial. PACT investigators. Plasminogen-activator angioplasty compatibility trial. J Am Coll Cardiol 1999;34:1954-62.
19. Bonnefoy E, Lapostolle F, Leizorovicz A. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Comparison of angioplasty and prehospital thromboysis in acute myocardial infarction study group. Lancet 2002;360:825-9.
20. Widimsky P, Groch L, Zelizko M, et al. Multicentre ransomised trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterisation laboratory: the PRAGUE study. Eur Heart J 2000;21:823-31.
21. Juliard JM, Himbert D, Critofini P. A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. Am J Cardiol 1999;83:305-10.
22. Loubervre C, Lefevre T, Louvard Y. Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent. Eur Heart J 2001;22:1128-35.
23. Collet JP, Montalescot G, Lesty C. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001;103:2328-31.
24. Moon JC, Kalra PR, Coats AJ. DANAMI-2: is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive centre? Int J Cardiol 2002;85:199-201.